SCHEMBL4776381

SCHEMBL4776381

COCCOc1cc2c(N3CCc4[nH]nc(C(=O)NC5CC5)c4C3)cnnc2cc1OC

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 6/20 0.39
KDR P35968 3/20 0.38
PDE10A Q9Y233 5/20 0.38
FLT1 P17948 2/20 0.37
PDPK1 O15530 1/20 0.37
FGFR1 P11362 1/20 0.36
NSD2 O96028 1/20 0.36
CHEK1 O14757 1/20 0.35
CHEK2 O96017 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
CSF1R P07333 1/20 0.35
KIT P10721 1/20 0.35
FLT3 P36888 1/20 0.35
AXL P30530 1/20 0.35
EHMT2 Q96KQ7 1/20 0.35
EHMT1 Q9H9B1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4794026 0.94 PDGFRB (0.42) PDGFRBKDRPDE10ANPC1RAB9A
SCHEMBL4169606 0.89 NTRK1 (0.37) PDGFRBKDRPDE10ANPC1RAB9A
SCHEMBL4762791 0.79 ENPP1 (0.51) PDGFRBKITFLT3
SCHEMBL4794767 0.78 PDE10A (0.41) PDGFRBKDRPDE10AFLT1FGFR1
SCHEMBL5487906 0.74 PDE10A (0.53) PDE10A
SCHEMBL5305892 0.73 PDGFRB (0.44) PDGFRBKDRPDE10AFLT1PDPK1
SCHEMBL4776555 0.72 PDPK1 (0.49) PDGFRBKDRPDE10AFLT1PDPK1
SCHEMBL4983355 0.70 PDE10A (0.44) PDGFRBKDRPDE10A
SCHEMBL4760284 0.70 ENPP1 (0.49) PDGFRB
SCHEMBL4761702 0.69 ACHE (0.50) PDGFRBPDE10AKITFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1991531-A1 CINNOLINE AND QUINOXALINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-11-19 EP disclosed
US-20070287707-A1 Phosphodiesterase 10 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2007-12-13 US disclosed
US-20070287707-A1 Phosphodiesterase 10 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2007-12-13 US disclosed
US-20070287707-A1 Phosphodiesterase 10 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2007-12-13 US disclosed
WO-2007100880-A1 CINNOLINE AND QUINAZOLINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-09-07 WO disclosed
WO-2007100880-A1 CINNOLINE AND QUINAZOLINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287707-A1 Phosphodiesterase 10 inhibitors PDE7A, PDE7B, PDE10A PDGFRB 3556/4885KDR 4714/4885PDE10A 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.